Tony Giordano is the typical biotech entrepreneur. As CEO of TheraVasc, he juggles fundraising with traveling the road to FDA approval, which can often times be long and costly, and doing it all with a lean workforce. But he's found an incredibly effective model to balance capital needs with the restructuring of a workforce: Interns.
In fact, it was an intern who helped Tony submit his latest Investigational New Drug (IND) application to the FDA to study the safety and biological activity of a TheraVasc drug. It might seem obvious or even slightly trivial, but interns offer startups a hardworking, forward-thinking labor pool at a heck of a price.
To read the full, original article click on this link: John Dearborn: Interns: A Startup's New Best Friend
Author: John Dearborn
